Research Square vs bioRxiv: Ownership & Fees

Research Square vs bioRxiv is, at its core, a nonprofit-versus-commercial question: Research Square is a preprint platform owned by the for-profit publisher Springer Nature, while bioRxiv and medRxiv are nonprofit servers now governed by openRxiv, an independent 501(c)(3) that took over from Cold Spring Harbor Laboratory (CSHL) in March 2025. Both are free for authors to use, but the ownership structure behind each one shapes fees, licensing control, data governance and long-term archival continuity in ways that matter for anyone advising authors on where to post.

A preprint server is an online platform where researchers deposit manuscripts before, or independently of, formal peer review. Research Square, bioRxiv and medRxiv are three of the most widely used servers in the life, health and biomedical sciences, and authors are increasingly asked to choose between them without understanding what sits behind each brand.

• What is the core difference between Research Square and bioRxiv?
• Who pays, and how is each platform funded?
• Who owns and controls author data?
• What long-term archival guarantees does each model offer?
• Common questions about Research Square and bioRxiv
• What this means for authors and research administrators

What Is the Core Difference Between Research Square and bioRxiv?

The core difference is legal ownership and mission accountability, not scope or screening rigour. Research Square traces to American Journal Experts (AJE); Springer Nature took a minority stake in the Research Square platform in 2018, became majority owner in 2020, and completed full acquisition of Research Square Company in 2022. It is, today, a wholly commercial subsidiary of a for-profit publishing group.

bioRxiv was founded in 2013 by John Inglis and Richard Sever at CSHL, a nonprofit research institution. medRxiv followed in 2019 as a partnership between CSHL, Yale University and BMJ. In March 2025, governance of both servers passed from CSHL to openRxiv, a newly formed independent nonprofit whose stated mission is “creating opportunities for sharing, discovering, and advancing preprints in the life and health sciences” — with a dedicated board and a Scientific and Medical Advisory Board of researchers overseeing policy.

Who Pays, and How Is Each Platform Funded?

Neither model charges authors to post a preprint — that much is identical. What differs is where the money to run the platform comes from, and what that implies about future incentives. Research Square’s operating costs are absorbed by Springer Nature’s commercial publishing business and by AJE’s paid author-services division (editing, translation and related products), which Research Square continues to cross-sell alongside free preprint posting.

openRxiv, by contrast, depends on renewable philanthropic and institutional grants rather than a parent company’s revenue. Its principal funders include the Chan Zuckerberg Initiative, the Sergey Brin Family Foundation, the Robert Lourie Foundation and a consortium of supporting universities including Caltech, MIT, Stanford, Yale and the University of Washington. That is a genuine trade-off, not a straightforward win for either side:

• Research Square’s commercial backing gives it predictable, revenue-linked funding, but ties its long-term direction to Springer Nature’s corporate strategy.
• openRxiv’s nonprofit funding is mission-locked by governance structure, but depends on grant renewal cycles rather than a guaranteed revenue stream.

Who Owns and Controls Author Data?

Ownership of the underlying manuscript stays with authors on both platforms — this is not a copyright grab by either side. The meaningful difference is licensing control and third-party data access. Research Square requires every posted preprint to carry a CC-BY 4.0 licence, which is the most permissive open licence and maximises reuse rights for readers, but leaves authors no choice in the matter.

bioRxiv and medRxiv give authors a menu of licence options — CC0, CC-BY, CC-BY-NC, CC-BY-ND, CC-BY-NC-ND, or a “no reuse without permission” setting — and authors can change the licence on an existing preprint after posting. That is more author control, though funders that mandate CC-BY (a growing norm, including under several cOAlition S-aligned policies) require authors to actively select it rather than receiving it by default.

The two models also diverge sharply on bulk data access. openRxiv publishes a full monthly XML/PDF text-and-data-mining corpus through a requester-pays AWS S3 bucket, alongside a public metadata API — an open-infrastructure commitment consistent with nonprofit, grant-funded governance. Research Square does not publish an equivalent bulk TDM feed; third-party discovery of Research Square content runs through Crossref DOI metadata and the platform’s own search interface rather than a dedicated open corpus.

What Long-Term Archival Guarantees Does Each Model Offer?

Both platforms use the same third-party preservation service: Portico provides perpetual-access archiving for preprints posted to Research Square, bioRxiv and medRxiv alike, so the archive itself is not where the two models diverge.

The real difference is organisational continuity risk. A commercial platform’s archival commitments are ultimately corporate policy that could change with ownership or strategy; a nonprofit platform’s commitments are set by a mission-bound board, though it carries the separate risk of grant-funding renewal. Advising authors on a multi-decade preprint record means treating “who governs the archive” as distinct from “where is the archive stored.”

Common Questions About Research Square and bioRxiv

Is bioRxiv reputable?

Yes. bioRxiv is widely cited across molecular and cell biology, screens submissions for plagiarism and non-scientific content, and is now governed by openRxiv, an independent nonprofit with a Scientific and Medical Advisory Board. Its reputation rests on community adoption and transparent, nonprofit governance rather than commercial incentives.

Does bioRxiv count as published?

No. A bioRxiv or medRxiv preprint is not peer-reviewed and does not constitute formal publication. The ICMJE treats preprints as legitimate scholarly communication, not duplicate publication, but funders and REF-style assessment exercises generally still require the peer-reviewed version for compliance credit.

Is bioRxiv a preprint?

bioRxiv is not itself a preprint — it is the server that hosts preprints. A preprint is the individual manuscript version posted before or independent of peer review; bioRxiv is the nonprofit infrastructure, now under openRxiv, that makes that posting possible for life-science research.

What are the alternatives to bioRxiv?

Alternatives include medRxiv for clinical and public-health research, Research Square for multidisciplinary and journal-integrated posting, and repository-style options such as arXiv, the Open Science Framework, Figshare and Zenodo. The right choice depends on discipline, human-subjects status and whether journal-integrated posting matters.

What This Means for Authors and Research Administrators

For most authors, the nonprofit-versus-commercial distinction will not change whether posting is free — it usually is, on both models. It should change how administrators frame the advice they give:

• Explain that Research Square’s mandatory CC-BY licence maximises reuse but removes licensing choice, while bioRxiv/medRxiv give authors more control over which licence applies.
• Flag that researchers doing large-scale corpus analysis will find far richer bulk access through openRxiv’s TDM feeds than through Research Square.
• Note that archival preservation (Portico) is equivalent across models — the open question is who controls future platform policy, not the archive.
• Treat commercial ownership as a disclosure point, not a disqualifier: Springer Nature’s backing gives Research Square’s In Review workflow journal-integration value a nonprofit model does not replicate.

As more research administration offices build formal preprint guidance into their researcher-facing documentation, the originating business model behind a server deserves the same disclosure as its discipline coverage or screening depth. Authors are entitled to know not just where their manuscript will sit, but who ultimately governs the platform holding it — a nonprofit board answerable to a research mission, or a commercial parent answerable to shareholders.

Last updated: 3 July 2026.